President Donald Trump, Robert F. Kennedy Jr., and Dr. Mehmet Oz held a press conference announcing a controversial connection between Tylenol use during pregnancy and an increased risk of autism in children. The event, widely publicized, sparked immediate debate over the implications for public health.
Trump asserted that Tylenol “can be associated with a very increased risk of autism” when taken during pregnancy, urging women to limit its use unless medically necessary. He framed the disclosure as part of a broader effort to address what he called a “horrible, horrible crisis” of autism. The president also hinted at additional announcements regarding vaccines, though no specific details were provided.
The White House press secretary, Karoline Leavitt, described the announcement as targeting the “childhood autism epidemic,” emphasizing the administration’s commitment to uncovering root causes of chronic conditions. However, the statement lacked immediate clarification on the scientific basis for the claims.
Tylenol manufacturer Kenvue, Inc. saw its stock drop 7% following the press conference, reflecting investor concern. Meanwhile, RFK Jr. suggested environmental factors, including medication use, contribute to rising autism rates, though he acknowledged further research is needed.
The discussion also touched on leucovorin, a drug approved by the FDA for treating cerebral folate deficiency in some children with autism. While clinical studies indicate potential benefits for specific symptoms, experts caution it is not a cure and requires targeted medical evaluation.
No official response from the Centers for Disease Control and Prevention or the American College of OBGYN was included in the report. The press conference concluded with Trump’s assertion that more revelations about autism would emerge in the coming years.